A method for treating patients with COVID-19 and/or other respiratory conditions include administering a dosage of 75-100 milligrams of dapsone twice daily. A variety of dapsone formulation and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.

Methods and devices for coating a respiratory system and thereby protecting from or killing viral, bacterial, or viral and bacterial infections are disclosed. An active compound that is a virucide, a bactericide, or both, is vaporized by a vaporizing device and inhaled into the respiratory system where the active compound coats the respiratory system.

A system may limit the number of times an inhalation device transmits inhalation data to a single time to reduce the battery usage of the inhalation device. The system may include an inhalation device that has medicament and an electronics module. The system may limit the number of times the inhalation device transmits new inhalation data to any mobile device to a single time by causing the server to receive the new inhalation data from one of the mobile devices and causing the server to transmit the new inhalation data to other of the mobile devices prior to the other mobile devices transmitting a request for the new inhalation data to the inhalation device. The inhalation device may include a Quick Response (QR) code, and a mobile application may determine at least one of a medication type or a number of doses of the inhalation device from the QR code.

A device for delivering a predetermined volume a substance within a body cavity. The device includes: at least one predefined volume sized and shaped to contain a predetermined volume the substance; a delivery end in fluid communication with a container; and at least one valve mechanically connected to the container and configurable between an active configuration in which the valve enables delivery of a volume of the substance and an inactive configuration, in which the valve prevents delivery.

An aerosol unit for an aerosol dispenser, which aerosol unit comprises an axially oriented body, having a distal inlet part and a proximal outlet part; a carrier member arranged in the body, transversally to the axis between the inlet part and the outlet part; and wherein the carrier member comprises through-holes which place the inlet part in fluid communication with the outlet part, and wherein the carrier member is insert-moulded into the body such that a contact surface between the carrier and the body forms an air-tight seal.

In general, systems and methods for controlling operation of drug administration devices using surgical hubs are provided.

In general, systems and methods for monitoring and communicating information using drug administration devices are provided.

The present disclosure provides methods of treatment of COVID-19 through pH modulation of the respiratory tract using a controlled delivery device. In some embodiments, the controlled delivery device includes an aerosolizer, a microprocessor, and a syringe. The controlled delivery device can be integrated with a humidifier or a ventilator. In some embodiments, two agents are delivered in conjunction using the controlled delivery device. In some embodiments, one agent is a physiologically compatible alkalizing agent, such as an aqueous solution of sodium bicarbonate of strength 3%-8.4% at a pH ranging from 8 to 8.6 at 20° C. In some embodiments, one agent is an anti-inflammatory agent, such as corticosteroid ciclesonide.

The present invention relates to a medicament delivery device comprising a generally tubular distal housing part (10; 110) having opposite proximal and distal ends, wherein third mechanically coded interface means (11; 111) are arranged on its proximal end; a generally tubular proximal housing (20; 120) part having opposite proximal and distal ends and being releasibly connected to said distal housing part, wherein with fourth mechanically coded interface means (22; 122) are arranged on its distal end; a medicament container having a slidable stopper, wherein said container is arranged to be positioned within said proximal housing part; a plunger rod (60; 160) arranged within said distal housing; drive means arranged within said distal housing and being operably connected to said plunger rod for driving said plunger rod and thereby said stopper towards the proximal end of the device; wherein said device further comprises an interface member (50; 150) comprising first (51; 151) and second (52; 152) mechanically coded interface means arranged to match and interact with the third (11; 111) and the fourth (22; 122) mechanically coded interface means when the distal and the proximal housing parts are connected to each other.

A flap (20) for an inhalation actuated mechanism (18) of a powder inhaler (1) comprises a base member (29), a skirt structure (24) projecting from a surface of the base member (29), and a coupling portion (21) to be coupled to a resilient member (40′) of the inhalation actuated mechanism (18).